TECHWIRE 30
(CIX: WRAL30)  1,114.46  up arrow+5.13  (0.46 %)  Updated: 06:40 PM EDT, Sep 16 2014
(NQ: Apple)  100.86  down arrow-0.77  (-0.76 %)  Updated: 05:20 PM EDT, Sep 16 2014
(NY: QUINTILES)  57.16  down arrow-0.09  (-0.16 %)  Updated: 06:40 PM EDT, Sep 16 2014
(OP: BASF SE)  99.08  down arrow-0.66  (-0.66 %)  Updated: 05:20 PM EDT, Sep 16 2014
(NQ: BioCryst)  11.34  down arrow-0.11  (-0.96 %)  Updated: 05:20 PM EDT, Sep 16 2014
(NQ: BioDelivery)  17.23  up arrow+0.4  (2.38 %)  Updated: 05:20 PM EDT, Sep 16 2014
(NQ: CEMP)  9.91  up arrow+0.12  (1.23 %)  Updated: 05:20 PM EDT, Sep 16 2014
(NQ: Cisco Systems)  25.22  up arrow+0.16  (0.64 %)  Updated: 05:20 PM EDT, Sep 16 2014
(NQ: Cree)  41.63  up arrow+0.53  (1.28 %)  Updated: 05:20 PM EDT, Sep 16 2014
(NQ: DARA)  1.14  down arrow-0.03  (-2.56 %)  Updated: 05:20 PM EDT, Sep 16 2014
(NY: EMC CORPORATION)  29.55  up arrow+0.09  (0.31 %)  Updated: 06:40 PM EDT, Sep 16 2014
(NQ: Extreme Networks)  4.98  up arrow+0.12  (2.47 %)  Updated: 05:20 PM EDT, Sep 16 2014
(NQ: FB)  76.08  up arrow+1.5  (2.01 %)  Updated: 05:20 PM EDT, Sep 16 2014
(NY: GLAXOSMITHKLINE)  47.30  up arrow+0.32  (0.68 %)  Updated: 06:40 PM EDT, Sep 16 2014
(NQ: GOOG)  579.95  up arrow+6.85  (1.2 %)  Updated: 05:20 PM EDT, Sep 16 2014
(NY: IBM)  192.96  up arrow+1.15  (0.6 %)  Updated: 06:40 PM EDT, Sep 16 2014
(NY: LH)  107.01  up arrow+1.15  (1.09 %)  Updated: 06:40 PM EDT, Sep 16 2014
(OP: Lenovo Group)  30.38  down arrow-0.4  (-1.3 %)  Updated: 05:20 PM EDT, Sep 16 2014
(NY: MRK)  59.99  up arrow+0.47  (0.79 %)  Updated: 06:40 PM EDT, Sep 16 2014
(NQ: Microsoft Corp)  46.76  up arrow+0.52  (1.12 %)  Updated: 05:20 PM EDT, Sep 16 2014
(NQ: NTAP)  42.97  up arrow+0.11  (0.25 %)  Updated: 05:20 PM EDT, Sep 16 2014
(NY: NOVARTIS AG)  94.38  up arrow+0.2  (0.21 %)  Updated: 06:40 PM EDT, Sep 16 2014
(OP: Novozymes A/S)  45.07  up arrow+0.07  (0.16 %)  Updated: 05:20 PM EDT, Sep 16 2014
(NY: PFIZER)  30.05  up arrow+0.13  (0.43 %)  Updated: 06:40 PM EDT, Sep 16 2014
(NQ: Pozen)  8.09  up arrow+0.2  (2.53 %)  Updated: 05:20 PM EDT, Sep 16 2014
(NY: RED HAT)  60.73  up arrow+1.04  (1.74 %)  Updated: 06:40 PM EDT, Sep 16 2014
(NQ: BBRY)  11.06  up arrow+0.04  (0.36 %)  Updated: 05:20 PM EDT, Sep 16 2014
(NQ: Salix)  155.87  up arrow+7.15  (4.81 %)  Updated: 05:20 PM EDT, Sep 16 2014
(NQ: SQI)  16.28  down arrow-0.33  (-1.99 %)  Updated: 05:20 PM EDT, Sep 16 2014

Posts tagged “liquidia”

Updated November 12, 2013

Premium Lock Liquidia spins out new venture with $25M in funding

Envisia Therapeutics, a spinout from Triangle-based nanotechology firm Liquidia, formally launched on Tuesday with investors committing $25 million to the new venture. The company will be run by Liquidia's current management team.

Envisia Therapeutics Envisia Therapeutics

Updated November 12, 2013

Premium Lock Exclusive: Wearing two caps is next challenge for Liquidia-Envisia leadership

CEO Neal Fowler and the management team at Liquidia will be handling multiple roles as the nantotechnology firm formally spins out Envisia with $25 million in new funding. Fowler discusses the challenges and opportunities in an exclusive WRALTechWire Insider interview.

Neal Fowler  Neal Fowler

October 30, 2013

Premium Lock Kenan Institute director DeSimone to step down at end of the year

Joseph DeSimone Joseph DeSimone, whose nanotechnology research in University of North Carolina at Chapel Hill labs formed the basis for spinout Liquidia Technologies, will step down as director of UNC's Kenan Institute of Private Enterprise 18 months after taking the top position.

Updated May 21, 2013

Premium Lock Nanotech firm Liquidia extends PATH pneumonia vaccine partnership

Liquidia Liquidia Technologies is applying its proprietary nanoparticle manufacturing process to the development of a broader and more affordable pneumonia vaccine.

May 7, 2013

Premium Lock Liquidia's preclinical studies offer insight into new company's plans

Liquidia This week Liquidia presented data from two preclinical studies at the annual meeting of the Association for Research in Vision and Ophtalmology, studies that offer a peek at ophtalmic applications Liquidia has been researching.

Updated May 2, 2013

Premium Lock Nanotech firm Liquidia eyes ophthalmology opportunity with new company

Nanotechnology company Liquidia plans to spin off a separate company. Read more about the therapeutic and financial opportunities Liquidia sees in eye drugs.

Updated March 6, 2013

Premium Lock Liquidia mulls spinning off two nanotechnology companies

Liquidia CED Life Science Conference 2013: Nanotechnology company Liquidia is considering spinning its research off into one, perhaps even two companies to pursue different targets utilizing its proprietary nanoparticle technology.

December 13, 2011

Premium Lock Liquidia to pursue new pneumonia vaccine

Liquidia The Research Triangle Park-based firm is working with PATH to conduct preclinical studies on a "next generation" pneumococcal vaccine that could be more effective than existing vaccines and more efficient to produce.

Updated May 12, 2010

Premium Lock Medical device startup lands former Liquidia COO as marketing exec

Luke Roush Todd Pope, the CEO at venture-backed TransEnterix, hires Luke Roush as vice president for marketing. Pope is a former Liquidia CEO.

Techwire Inside Partners
The Skinny: A Blog by Rick Smith

OUR INSIDERS

Dr. Mike Walden
Tech economy
Frank Vinluan
Life science
Vivek Wadhwa
Commentary
Scroll